Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →LogicBio Therapeutics has voluntarily halted its SUNRISE gene-editing trial in pediatric methylmalonic acidemia after the death of a second patient, casting…
AstraZeneca's rare disease unit Alexion is taking out cash-strapped gene therapy developer LogicBio Therapeutics in a $68 million deal that gives the U.K.…
Alexion, AstraZeneca's Rare Disease unit, announced plans to acquire clinical-stage genomic medicines company LogicBio Therapeutics in a $68 million all-cash…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Alexion (AstraZeneca Rare Disease) acquired LogicBio Therapeutics for $2.07/share (~$70M) via tender offer to gain LogicBio's GeneRide non-nuclease genome editing platform and rare-disease R&D team. Tender offer closed Nov 15, 2022; LogicBio became a wholly owned subsidiary Nov 16, 2022.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / LogicBio Therapeutics Inc. (this deal) | 2022 | $70M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2022 deals · AstraZeneca PLC deals · Rare Disease deals